The PanACEA study is one of the first adaptive model-based dose-finding studies for a tuberculosis drug, and the first of its kind to be conducted in Africa. The study proves that the active substance BTZ-043 is antibacterially effective and well tolerated and can also be administered in combination with other tuberculosis drugs. The safety and tolerability of BTZ-043 was investigated in 77 adults with newly diagnosed pulmonary tuberculosis in Cape Town, South Africa. Publication